Filtros de búsqueda

Lista de obras de Fotios Loupakis

"HER majesty's a pretty nice girl but she changes from day to day".

artículo científico publicado en 2011

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer

artículo científico

A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.

artículo científico publicado en 2008

A perspective on the current management of advanced colorectal cancer

artículo científico publicado en 2013

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

artículo científico publicado en 2008

A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab

artículo científico publicado en 2017

AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3

artículo científico publicado en 2019

Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases

artículo científico publicado en 2013

Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.

artículo científico publicado en 2011

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.

artículo científico publicado en 2016

Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.

artículo científico publicado en 2017

Are Dose-Finding Studies Still Necessary When Targeted Therapy Is Associated With Chemotherapy?

artículo científico publicado en 2006

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

artículo científico

Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases

scientific article published on 06 September 2018

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

artículo científico publicado en 2015

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

artículo científico publicado en 2015

BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling

artículo científico publicado en 2017

BRAF-mutated metastatic colorectal cancer between past and future.

artículo científico publicado en 2015

Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.

artículo científico publicado en 2014

Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle

artículo científico publicado en 2011

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

artículo científico publicado en 2010

Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer

artículo científico publicado en 2009

Biomarkers and response to bevacizumab--letter

scientific article published on 01 February 2014

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

artículo científico publicado en 2015

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy

artículo científico publicado en 2016

Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers.

artículo científico publicado en 2018

Cancer dormancy: a model of early dissemination and late cancer recurrence.

artículo científico publicado en 2011

Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis

artículo científico publicado en 2013

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

artículo científico publicado en 2010

Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?

artículo científico publicado en 2010

Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.

artículo científico publicado en 2009

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients

artículo científico publicado en 2010

Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.

artículo científico publicado en 2012

Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases

artículo científico publicado en 2019

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

artículo científico publicado en 2011

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

artículo científico publicado en 2012

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.

artículo científico publicado en 2015

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

artículo científico publicado en 2015

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

artículo científico publicado en 2015

Correction to: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases

artículo científico publicado en 2019

Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.

artículo científico publicado en 2011

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.

artículo científico publicado en 2017

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

scientific article published on 06 February 2019

Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.

artículo científico publicado en 2012

Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.

artículo científico publicado en 2014

Do we need biopsies of metastases for colorectal cancer patients?

artículo científico publicado en 2009

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.

artículo científico publicado en 2013

EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle

artículo científico publicado en 2012

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

artículo científico publicado en 2015

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

artículo científico publicado en 2016

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

artículo científico publicado en 2009

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.

artículo científico publicado en 2011

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

artículo científico publicado en 2014

FOLFOXIRI and bevacizumab for metastatic colorectal cancer

artículo científico publicado en 2015

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

artículo científico publicado en 2013

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.

artículo científico publicado en 2016

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

artículo científico publicado en 2013

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

artículo científico publicado en 2015

First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer

artículo científico publicado en 2006

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

artículo científico publicado en 2015

First-line chemotherapy for mCRC—a review and evidence-based algorithm.

artículo científico

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.

artículo científico publicado en 2013

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

artículo científico publicado en 2018

Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.

artículo científico publicado en 2014

Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan

artículo científico publicado en 2010

Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.

artículo científico publicado en 2014

Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.

artículo científico publicado en 2016

High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice

artículo científico publicado en 2010

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

artículo científico publicado en 2008

High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease

artículo científico publicado en 2012

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.

artículo científico publicado en 2013

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.

artículo científico publicado en 2017

Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy.

artículo científico publicado en 2010

Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

artículo científico publicado en 2010

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials

artículo científico publicado en 2017

Influence of sex on the survival of patients with esophageal cancer.

artículo científico publicado en 2012

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

artículo científico publicado en 2014

Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.

artículo científico publicado en 2010

Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer

artículo científico publicado en 2014

Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis

scientific article published on 09 April 2020

KRAS and BRAF genotyping of synchronous colorectal carcinomas

artículo científico publicado en 2014

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

artículo científico publicado en 2009

Liquid biopsy: monitoring cancer-genetics in the blood

artículo científico publicado en 2013

Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases

artículo científico publicado en 2009

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

artículo científico publicado en 2010

Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer

artículo científico publicado en 2015

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.

artículo científico publicado en 2018

New perspectives for TAS-102: TASK successful?

artículo científico publicado en 2017

Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy

article

Optimal approach to potentially resectable liver metastases from colorectal cancer

artículo científico publicado en 2008

Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology

artículo científico publicado en 2015

Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.

artículo científico publicado en 2011

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

artículo científico publicado en 2012

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

artículo científico publicado en 2009

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

artículo científico publicado en 2011

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer

artículo científico publicado en 2008

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy

scientific article published on 01 April 2007

Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.

artículo científico publicado en 2018

Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction

artículo científico publicado en 2008

Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.

artículo científico publicado en 2010

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.

artículo científico publicado en 2015

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer

artículo científico publicado en 2015

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.

artículo científico publicado en 2017

Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes

scientific article published on 22 January 2020

Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?

artículo científico publicado en 2010

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

artículo científico publicado en 2015

Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.

artículo científico publicado en 2011

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

artículo científico publicado en 2018

Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study

scientific article published on 08 June 2018

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management

artículo científico publicado en 2015

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

artículo científico publicado en 2015

Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients

artículo científico publicado en 2014

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab

artículo científico publicado en 2013

Publisher Correction: Shared heritability and functional enrichment across six solid cancers

scientific article published on 23 September 2019

QoL is a cool tool.

artículo científico publicado en 2017

Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.

artículo científico publicado en 2016

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.

artículo científico publicado en 2010

Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.

artículo científico publicado en 2009

Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'

artículo científico publicado en 2013

Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

artículo científico publicado en 2010

Response

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

artículo científico publicado en 2011

Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.

artículo científico publicado en 2014

Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.

artículo científico publicado en 2013

Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies

artículo científico publicado en 2019

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

artículo científico publicado en 2017

Shared heritability and functional enrichment across six solid cancers

artículo científico publicado en 2019

Shared heritability and functional enrichment across six solid cancers

Should oncologists be aware in their clinical practice of KRAS molecular analysis?

artículo científico publicado en 2011

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

artículo científico publicado en 2017

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

artículo científico publicado en 2015

Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer

artículo científico publicado en 2017

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis

artículo científico publicado en 2016

TAS-102 for the treatment of metastatic colorectal cancer.

artículo científico publicado en 2015

TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply

artículo científico publicado en 2015

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

artículo científico publicado en 2017

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

artículo científico publicado en 2018

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

artículo científico publicado en 2020

The possible role of chemotherapy in antiangiogenic drug resistance.

artículo científico publicado en 2012

The role of pharmacogenetics in the new ESMO colorectal cancer guidelines.

artículo científico publicado en 2017

The role of tumor angiogenesis as a therapeutic target in colorectal cancer

artículo científico publicado en 2018

Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.

artículo científico publicado en 2016

Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer

artículo científico publicado en 2006

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

scientific article published on 08 November 2019

Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.

artículo científico publicado en 2008

VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population.

artículo científico publicado en 2008

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

artículo científico publicado en 2016

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.

artículo científico publicado en 2015

Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer

scientific article published on 23 December 2008

Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity

scientific article published on 01 May 2007

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.

artículo científico publicado en 2017

miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda